Left Atrial Appendage Management Options in Persistent Atrial Fibrillation

Primary Management: Oral Anticoagulation

The European Society of Cardiology recommends direct oral anticoagulants (DOACs) as first-line therapy for stroke prevention in patients with persistent atrial fibrillation, as they are superior to vitamin K antagonists (VKAs) in preventing thromboembolism and have lower risk of intracranial hemorrhage 1, 2
A target INR of 2.0-3.0 is recommended for patients prescribed a VKA for stroke prevention when DOACs are contraindicated, according to the European Society of Cardiology 1, 2
The European Society of Cardiology does not recommend antiplatelet therapy alone as an alternative to anticoagulation for stroke prevention in atrial fibrillation patients 1, 2
The need for anticoagulation should be based on thromboembolic risk assessment using the CHA₂DS₂-VASc score, not on the temporal pattern of atrial fibrillation, as recommended by the European Society of Cardiology 2

The European Society of Cardiology recommends surgical closure of the left atrial appendage as an adjunct to oral anticoagulation in patients with atrial fibrillation undergoing cardiac surgery (Class I, Level B) 1, 2
Surgical left atrial appendage closure should be considered as an adjunct to oral anticoagulation in patients with atrial fibrillation undergoing endoscopic or hybrid atrial fibrillation ablation, according to the European Society of Cardiology 3, 4
Stand-alone endoscopic surgical closure of the left atrial appendage may be considered in patients with atrial fibrillation who have contraindications for long-term anticoagulant treatment, as recommended by the European Society of Cardiology 3, 4

The American Heart Association suggests that left atrial appendage occlusion devices may be considered for high-risk patients with atrial fibrillation who are deemed unsuitable for anticoagulation (Class IIb, Level B) 5
Patients undergoing percutaneous left atrial appendage closure typically require at least 45 days of post-procedural anticoagulation, which must be considered in the risk assessment, according to the American Heart Association 5

For patients with breakthrough stroke despite appropriate anticoagulation, adding left atrial appendage closure may be considered, but adding antiplatelet therapy to anticoagulation is not recommended, as suggested by the European Society of Cardiology 2, 4
In patients with end-stage renal disease on hemodialysis, warfarin remains the anticoagulant of choice, as there are limited data for direct oral anticoagulants in this population, according to the American Heart Association 6
For patients with mechanical heart valves or moderate-to-severe mitral stenosis, vitamin K antagonists remain the recommended anticoagulation strategy rather than direct oral anticoagulants, as recommended by the European Society of Cardiology 2

For patients on vitamin K antagonists, INR should be monitored regularly with a target of 2.0-3.0, as recommended by the European Society of Cardiology 2
Patients with inadequate time in therapeutic range on vitamin K antagonists (TTR <70%) should be switched to a direct oral anticoagulant if eligible, according to the European Society of Cardiology 1
Regular reassessment of thromboembolic risk is recommended in all atrial fibrillation patients to ensure appropriate anticoagulation management, as suggested by the European Society of Cardiology 1, 3